Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vasili Karas

Adult Reconstructive Orthopaedic Surgery Chicago, IL Medical Doctor

NPI 1063778413 CMS profile 2788805

1611 W Harrison St Ste 400, Chicago, IL 60612

Open in the dashboard

General payments

$263,806

391 records reported · program years 2019–2025

Research payments

$6,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$444,885

2 holdings reported · through program year 2025

Research they led as principal investigator

$44,950 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Vasili Karas of Chicago, IL is reported in the CMS Open Payments database as having received $263,806 across 391 general payments and $6,000 in research payments paid to them. Separately, studies naming them as principal investigator received $44,950 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $444,885 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,163 33
2024 General $133,798 84
2023 General $10,594 87
2022 General $23,582 67
2021 General $55,287 55
2021 Research $6,000 1
2020 General $10,159 22
2019 General $12,224 43
2025 Ownership $222,443 1
2024 Ownership $222,443 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vasili Karas
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Vasili Karas were reported at $18,163. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Vasili Karas Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $12,224 $1,416 $292–$9,336 $163
2020 $10,159 $647 $141–$6,474 $114
2021 $55,287 $1,073 $211–$6,497 $132
2022 $23,582 $1,217 $236–$6,299 $149
2023 $10,594 $1,082 $246–$6,818 $160
2024 $133,798 $1,575 $323–$8,944 $164
2025 $18,163 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OMNIlife science, Inc $202,695 212 payments
  2. Stryker Corporation $53,409 146 payments
  3. DePuy Synthes Products, Inc. $3,158 6 payments
  4. Encore Medical, LP $2,475 2 payments
  5. MicroPort Orthopedics Inc $761 5 payments
  6. MicroPort NaviBot International LLC $415 5 payments
  7. Zimmer Biomet Holdings, Inc. $322 5 payments
  8. Davol Inc. $153 1 payment
  9. DePuy Synthes Sales Inc. $147 2 payments
  10. Arthrex, Inc. $118 1 payment
  11. Other $154 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $134,339 2 payments
  2. Consulting Fee $99,818 40 payments
  3. Travel and Lodging $14,450 47 payments
  4. Food and Beverage $14,224 301 payments
  5. Honoraria $975 1 payment
Products named General payments · program years 2019–2025
  1. Corin Technology $120,472 1 payment
  2. MAKO Knees, Hips $42,370 62 payments
  3. TRIATHLON $10,014 5 payments
  4. MAKO Knees, Hips $8,085 37 payments
  5. INSIGNIA $5,921 8 payments
  6. OMNIBotics 3.0 Technology - Knees $3,222 16 payments
  7. ACCOLADE $2,526 30 payments
  8. OMNIBotics 3.0 Implants $2,259 60 payments
  9. DJO Surgical Empowr Knee System $1,500 1 payment
  10. Various Products $1,019 61 payments
  11. Other $5,936 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. OMNIlife science, Inc $6,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,943

Median for Orthopedic Surgery: 203

Drug cost

$19,673

Median for Orthopedic Surgery: $1,433

Branded share of claims

7.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $8,226
Meloxicam Generic 330 $1,423
Pantoprazole Sodium Generic 139 $1,306
Ondansetron Odt Ondansetron Brand 114 $1,252
Tramadol Hcl Generic 286 $1,147
Cefadroxil Generic 83 $1,093
Oxycodone Hcl Generic 170 $900
Diclofenac Sodium Generic 70 $819
Mupirocin Generic 117 $762
Celecoxib Generic 19 $635

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$667,043

Of which drugs: $50,916

Medicare patients

1,012

Average age 72

Services billed

18,648

669 women, 343 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 24%
Diabetes 23%
Chronic kidney disease 17%
Depression 17%
Osteoporosis 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 38 50 $19,986
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 27 31 $16,253
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 19 928 $12,739
Injection, methylprednisolone acetate, 1 mg J1010 Office 124 13,162 $1,315
Injection, methylprednisolone acetate, 40 mg J1030 Office 56 146 $622

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record